Kornimate/medical-research-clean huggingface dataset:
rituximab and gemcitabine for patients with relapsed or refractory diffuse large b-cell lymphoma

Conditions: Lymphoma, B-Cell

Summary: rituximab has been demonstrated to sensitize drug-resistant nhl cells to the cytotoxic actions of several chemotherapy agents by enhancing sensitivity of tumor cells to chemotherapy-induced apoptosis. gemcitabine, a nucleoside analog that is used in several other malignancies, has shown very promising activity in patients with refractory hodgkin's disease and low-grade nhl. the combination of rituximab and gemcitabine may have synergistic cytotoxic action in patients with relapsed or refractory dlbcl and possibly lead to improved response rates and demonstrable clinical benefit. this trial will investigate the efficacy the combination of rituximab and gemcitabine in treating patients with relapsed or refractory dlbcl.

outline: this is a multi-center study. * rituximab 375 mg/m2 day 1 of 21 day cycle * gemcitabine 1000 mg/m2 days 1 and 8 of 21 day cycle subgroup 1. relapsed after responding to first line chemotherapy, who are not candidates for salvage high-dose chemotherapy. subgroup 2. failure to achieve a complete response or relapsed after responding to salvage chemotherapy (any number of salvage regimens allowed), who are not candidates for high-dose chemotherapy. subgroup 3. refractory to first line chemotherapy and/or 1 (one) salvage chemotherapy regimen. subgroup 4. progression after high-dose chemotherapy. patients with progressive disease within 3 months of high-dose chemotherapy are not allowed. performance status: ecog performance status 0, 1, 2 life expectancy: not specified hematopoietic:· * anc ≥ 1,000/mm3· * platelets ≥ 100,000/mm3 hepatic:· * total bilirubin ≤ 2.0 x uln· * alt and ast ≤ 3 x uln unless lymphoma involves the liver on ct scan then ast and alt can be \< 5 x uln renal:· * serum creatinine ≤ 2.0 mg/dl (except for patients on dialysis) cardiovascular:· * not specified pulmonary:· * not specified

Eligibility criteria:
inclusion criteria: * biopsy-proven dlbcl which meet the criteria of any of the 4 subgroups * transformed dlbcl from a previous indolent nhl which meet the criteria of any of the 4 subgroups and have received at least one standard chemotherapy regimen for aggressive nhl or a biopsy upon progression of disease has been obtained to confirm the presence of dlbcl. the concomitant presence of a component of low grade lymphoma will not exclude participation * measurable disease per standardized response criteria for non-hodgkin's lymphoma * prior gemcitabine therapy is allowed. * negative pregnancy test exclusion criteria: * no history of life-threatening reactions to rituximab. * no history of gemcitabine intolerance; prior gemcitabine therapy is allowed. * no history of malignancy in the last 5 years (basal cell carcinoma of the skin excluded). * no central nervous system or cerebrospinal fluid involvement * no other investigational drugs received within 30 days prior to being registered for protocol therapy. * no active infections. * no current breastfeeding

Keywords: lymphoma
blastocyst euploidy assessment and conditioned embryo transfer

Conditions: Infertility

Summary: the study is designed to evaluate the effectiveness of pre-implantation genetic screening (pgs) for infertility patients of advanced maternal age undergoing assisted reproductive treatment. half of the patients will have their embryos tested by pgs and 1 or 2 chromosomally normal embryos with the highest morphological grading transplanted back to the uterus. the other half of the participants will not have their embryos tested and 1 or 2 untested embryos with the highest morphological grading transplanted back to the uterus.

pgs is an assisted reproductive technology that screens patients embryos, discriminating between embryos with a normal set of chromosomes (euploid) and those with an abnormal set of chromosomes (aneuploid). in this study, we will apply a novel validated next generation sequencing technology called copy number variation sequencing (cnv-seq) to comprehensively screen a trophectoderm biopsy sample from patient's embryos for chromosomal abnormalities that commonly arise in human embryos. the hypothesis is that pgs performed using cnv-seq on embryos produced by patients with a poor prognosis for pregnancy (maternal age \> 35), followed by transfer of chromosomally normal euploid embryos, will result in significantly higher implantation, pregnancy and live birth rates and lower miscarriage rates compared to patients having no pgs.

Eligibility criteria:
inclusion criteria: * patient undergoing in vitro fertilization (ivf) * normal uterine function by ultrasound and absence of hysteromyoma * regular menstrual cycle of 25-35 days * normal hormone levels (who standard) for lh, prl, e2, prog, test and tsh * fsh 1-12 iu/l and follicle number \> 5 on day 2-3 of menstrual cycle * minimum of 3 blastocysts on day 5 of embryo development * signed consent form exclusion criteria: * known endometriosis * abnormal vaginal bleeding with no known cause * known genital organ system malformation, unsuitable to conceive * known currently active pelvic inflammation * abnormal liver, kidney lab results, with clinical implications. * known endocrine or metabolic disorders (pituitary gland, adrenal glands, pancreas, liver or kidney） * known ovarian, breast, uterine, adrenal glands, pituitary gland or hypothalamus tumor * known abnormal cervical cancer lesions, with clinical implications, within one year before pgs * history of chemo- or radio-therapy * seropositive for hiv, hep b, hep c or tppa/rpr (syphilis) * known ovarian poor response in previous cycles, i.e. after administration of gnrh for \> 20 days * more than 2 implantation failures * more than 2 miscarriages * known altered parental karyotype such as robertsonian or reciprocal translocation * use of sperm or oocyte donors * severe male factor (surgical retrieval of sperm) * preimplantation genetic diagnosis cycles for single gene diseases or sex selection * participation in other ivf research studies * patient refusal or inability to follow the protocol for any good reason, including clinical visit or lab test

Keywords: advanced maternal age aneuploidy
an exploration of genetic testing for prostate cancer susceptibility

Conditions: Prostate Cancer

Summary: study of the factors that affect interest in - and uptake of - genetic testing for variants that predispose to prostate cancer from the perspective of the patient.

this study will use a mixed methods approach to follow men as they move through the genetic testing process, from initial contact through to receiving their genetic testing results. a questionnaire will be used to measure variables at both baseline and after proceeding through the testing process. a small cohort of men will be invited to be interviewed to gather some in depth qualitative data about the issues that have arisen during the study process.

Eligibility criteria:
inclusion criteria: * men with a positive family history of prostate cancer. the definition of a positive family history will be: men with a first degree relative with prostate cancer diagnosed at \<70 years; men with two relatives with prostate cancer where at least on is diagnosed at \<70 years; men with three relatives with prostate cancer diagnosed at any age * age 40-69 years * no previous biopsy for raised psa * absence of any psychological, familial, sociological or geographic situation potentially hampering compliance with the study protocol and follow-up schedule. exclusion criteria: * previous prostate cancer * men from families where there is known to be a mutation in a high-risk prostate cancer gene * men who have had a prostate biopsy within the last 12 months.
the effects of three different modalities of exercise in patients with schizophrenia

Conditions: Schizophrenia

Summary: exercise has been shown to improve health in patients with schizophrenia. however, it remains unclear which modality of exercise reports better benefits. aim: to compare the effects of different modalities of exercise training on psychological and physiological variables in schizophrenia.

exercise has been shown to improve psychological, physiological, and biological correlates in patients with schizophrenia. however, it remains unclear which modality of exercise reports better health benefits. aim: to compare the effects of three different modalities of exercise (aerobic, strength, aerobic-strength) on psychological and physiological variables in patients with schizophrenia. design: randomized clinical trial

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * age between 18-65 years exclusion criteria: * patients with other mental diseases * patients with mental disabilities * patients who present motor or behavioral pathologies that prevent the realization of the exercise training.
lung cancer registry

Conditions: Lung Cancer; NSCLC Stage IV; NSCLC, Stage III; SCLC, Extensive Stage; SCLC, Limited Stage

Summary: lung cancer is the second most common cancer in austria with 2.868 men and 2.009 women diagnosed in 2016. reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer. therefore, lung cancer is the most common reason for cancer associated death in men and second most common reason in women. this malignant disease can be divided into two main groups: small cell lung cancer (sclc) and non-small cell lung cancer (nsclc). nsclc is a paradigm for personalized medicine, with an increasing number of targetable gene alterations. despite this growing diversity of molecular subtypes, in most patients no targetable mutation can be detected. for these patients check-point inhibitors with or without chemotherapy is the mainstay of the initial tumor therapy. until recently, little progress has been made in the treatment of sclc in last decades. recently, an overall survival benefit by the addition of an immune-checkpoint inhibitor to first-line chemotherapy for advanced sclc has been reported. despite the progress in the treatment of nsclc, the performance of predictive biomarkers is weak. therefore, the development of more precise prediction models is of great importance for the progress of personalized treatment strategies.

this registry is designed as multicenter observational cohort of patients with lung cancer. patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. this patient follow-up data will be obtained until patient death or loss to follow-up. for documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. participation in the registry must not interfere with treatment routines. only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic case report forms. to maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry. a written consent must be obtained prior to the input of data. no informed consent is required from deceased patients. data will be collected from all sites willing to participate.

Eligibility criteria:
inclusion criteria: * stage iii a-c and iv a-b nsclc * limited disease (ld) and extensive disease (ed) sclc) * patients ≥ 18 years exclusion criteria: - due to the non-interventional design of the registry there are no specific exclusion criteria.
impact of scapula position on functionality and balance in people with chronic low back pain

Conditions: Back Pain

Summary: chronic low back pain is defined as pain that lasts for more than 3 months or exceeds the expected recovery time.

chronic low back pain is defined as pain that lasts for more than 3 months or exceeds the expected recovery time.

Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-65 * individuals with low back pain for at least 3 months for the first group * not undergoing surgery related to the lumbar region * cases without lumbar steroid injection in the last 3 months * not having visual and hearing loss * having low back pain * cases without neurological problems * cases without tumor and infection in the lumbar region * exclusion criteria: * individuals under the age of 18 * individuals with low back pain for less than 3 months for the first group * not having a musculoskeletal or neuromuscular disease that limits mobility,
a study to evaluate the efficacy, safety, and pharmacokinetics of igpro20 in adults with dermatomyositis (dm)

Conditions: Dermatomyositis

Summary: this is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of igpro20 (subcutaneous ig) treatment in adult subjects with dermatomyositis (dm). the primary objective of this study is to assess the efficacy of igpro20 subcutaneous (sc) doses in comparison to placebo in adult subjects with dm, as measured by responder status based on total improvement score (tis) assessments.


Eligibility criteria:
inclusion criteria: * male or female subjects ≥ 18 years of age * diagnosis of at least probable idiopathic inflammatory myopathies (iim) per european league against rheumatism/american college of rheumatology (eular/acr) classification criteria which includes confirmation of dermatomyositis (dm) rash/manifestation, disease activity defined by presence of dm rash / manifestation or an objective disease activity measure * disease severity defined by physician global activity visual analog scale (vas) with a minimum value of 2.0 cm on a 10 cm scale and mmt-8 ≤ 142 or cdasi total activity score ≥ 14. * corticosteroid daily dose less than that or equal to 20 mg prednisolone equivalent exclusion criteria: * cancer-associated myositis * evidence of active malignant disease or malignancies diagnosed within the previous 5 years * physician global damage score ≥ 3, or clinically relevant improvement between screening visit and baseline
comparison of muscle specific and movement specific muscle energy technique in the management of mechanical neck pain: a randomized controlled trial.

Conditions: Neck Pain

Summary: the purpose of this study is to compare the effects of muscle-specific muscle energy technique and movement-specific muscle energy technique in terms of pain, function and cervical range of motion in persons with mechanical neck pain.


Eligibility criteria:
inclusion criteria: mechanical neck pain ranging from 40-80 mm on visual analogue scale (vas) age between 19-44 years pain or limitation on cervical motion - exclusion criteria: history of fracture, surgery or trauma in the neck cervical radiculopathy myelopathy spondylosis syringomyelia thoracic outlet syndrome infection malignancy inflammatory or rheumatic disorders vascular syndromes

Keywords: neck pain
prone position and renal resistive index

Conditions: Acute Respiratory Distress Syndrome; Acute Kidney Injury; Prone Position; Intra-Abdominal Hypertension

Summary: patients suffering from acute respiratory distress syndrome (ards) with a prone position (pp) indication will benefit from measurements of renal resistive index, intra-abdominal pressure (iap), urinary oxygen tension (upo2) and ventilatory mechanics in supine position (baseline iap), after 2 hours in pp at the current iap value, thirty minutes after patients' abdomen suspension in order to resume baseline iap and after patients' are turned back to supine position.


Eligibility criteria:
inclusion criteria: * ards patients according to berlin criteria, intubated, mechanically ventilated * with pao₂/fio₂ \< 150 mmhg, * neuromuscular blockade * with an indication of pp done by the physician in charge * possibility to differ pp for one hour * patients should be hemodynamically stable since at least 4 hours exclusion criteria: * pregnant or breast-feeding women * legal protection, no social security affiliation * pp contra-indication * nasogastric tube contra-indication * extra corporeal membrane oxygenation * acute kidney injury at inclusion according to k-dio criteria, chronic kidney disease defined as an estimated glomerualr filtration rate less than 30 ml/min/1.73m², kidney transplantation, renal artery stenosis, solitary kidney, albuminuria \> 1.25 mg/ml * cardiac arrhythmia * obesity * advanced cirrhosis
efficacy, safety of hypertonic lactate soln. as fluid resuscitation compared with ringer's lactate in post-cabg pats

Conditions: Low Cardiac Output

Summary: prospective, randomized, open-label study to assess the efficacy and safety of hypertonic lactate solution, compared to ringer's lactate as fluid resuscitation to maintain hemodynamic stability in post-coronary artery bypass grafting(cabg) patients. patients who were eligible received either hypertonic lactate solution or ringer's lactate post-cabg in the icu when fluid resuscitation was needed.

prospective, randomized, open-label study to assess the efficacy and safety of hypertonic lactate solution, compared to ringer's lactate as fluid resuscitation to maintain hemodynamic stability in post-coronary artery bypass grafting(cabg) patients. patients who were eligible received either hypertonic lactate solution or ringer's lactate post-cabg observed in the first 12 hours in the icu when fluid resuscitation was needed.

Eligibility criteria:
inclusion criteria: * patients who have given their written informed consent. * male or female, aged 18-75 years. * post-operative cabg on pump or off pump in icu. * patients who need fluid resuscitation. exclusion criteria: * combined operations. * need for intra aortic balloon pump (iabp). * patients with severe arrhythmia (vt, af rapid response, heart block). * severe hemodynamic imbalance. * severe bleeding and/or re-operation. * liver dysfunction(sgot and sgpt 2x normal). * renal failure (creatinine \>2 mg%).

Keywords: coronary artery bypass grafting i.v. cardiac output
multivessel balloon occlusion to investigate obstructive coronary artery disease and angina

Conditions: Stable Angina; Multivessel Coronary Artery Disease

Summary: orbita-moon is a double-blinded, placebo-controlled experimental study that aims to understand how the different coronary artery stenoses contribute to overall clinical angina in patients with multi-vessel coronary artery disease. this study will investigate the symptoms conferred by each stenosis, induced by experimental ischaemia, for 60 patients with multi-vessel coronary artery disease.


Eligibility criteria:
inclusion criteria: * eligibility for pci due to angina * anatomical evidence of significant multi-vessel coronary stenosis defined by either: 1. ≥70% stenosis in two or more coronary arteries of ≥2.5mm visual diameter stenosis, on invasive coronary angiography (ica) 2. severe stenosis in ≥2 coronary arteries of ≥ 2.5mm visual diameter stenosis, on ctca * physiological evidence of ischaemia with a positive test corresponding to the coronary arteries to be stented, on at least one of the following: * dobutamine stress echocardiogram * cardiac mri * myocardial perfusion study * invasive metrics of coronary physiology exclusion criteria: * recent acute coronary syndrome * previous coronary artery by-pass graft surgery (cabg) * significant left main stem disease * chronic total occlusion in the target artery(s) * moderate to severe valvular disease * moderate to severe left ventricular impairment * contraindication to pci or a drug-eluting stents * contraindication to antiplatelet therapy * contraindication to adenosine * pregnant * inability to consent

Keywords: angina multi-vessel coronary artery disease symptoms placebo-controlled symptom assessment
obesity and endogenous oxalate synthesis

Conditions: Obesity

Summary: the goal of this study is to determine if obesity is associated with increased endogenous oxalate synthesis as assessed by urinary oxalate excretion, which is a known risk factor for calcium oxalate kidney stones. the study will recruit adult participants without history of kidney stones. participants will * ingest fixed diets containing low amounts of oxalate for 4 days * collect 24-hr urine samples during the fixed diet

in this study the investigators propose to measure the excretion of urinary oxalate on a fixed diet with controlled amounts of oxalate, in individuals of varying body sizes without history of kidney stones. the 24-hr urinary oxalate excretion on such a low-oxalate normal calcium fixed diet is determined to be an appropriate surrogate for endogenous oxalate synthesis. screening phase. the study will enroll 60 individuals without history of kidney stones (30 males/30 females) at the university of alabama at birmingham (uab). screening will include blood complete metabolic profile, 24-hr urine specimens collected at home on self-selected diets and anthropometric measurements. dietary phase participants will ingest a low-oxalate (\<60 mg/day), normal calcium (1000 mg/day) fixed diet for 4 consecutive days, collect three 24-hr urines after 1 day of dietary equilibration and have a fasted blood draw on day 5.

Eligibility criteria:
inclusion criteria age 19-70 yrs body mass index \> 18.5 kg/m2 normal fasting serum electrolytes on comprehensive metabolic profile willing to ingest fixed diets exclusion criteria chronic kidney disease, estimated glomerular filtration rate \< 60 ml/mn/1.73m2 primary hyperoxaluria liver, endocrine or renal diseases or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: cystic fibrosis, cystinuria, uric acid stone former, nephrotic syndrome, sarcoidosis, renal tubular acidosis, primary hyperparathyroidism, neurogenic bladder, urinary diversion pregnancy or breast-feeding incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus active malignancy or treatment for malignancy within 12 months prior to screening utilization of immunosuppressive medication uncontrolled hypertension or diabetes

Keywords: oxalate obesity kidney stones